UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA₁c without causing weight gain or increased hypoglycaemia

Diabetes, obesity & metabolism, 2009-12, Vol.11 (12), p.1145-1152

2009

Volltextzugriff (PDF)

Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia

Diabetes, obesity & metabolism, 2009-12, Vol.11 (12), p.1145-1152

2009

Volltextzugriff (PDF)

Efficacy and Tolerability of the DPP-4 Inhibitor Alogliptin Combined with Pioglitazone, in Metformin-Treated Patients with Type 2 Diabetes

The journal of clinical endocrinology and metabolism, 2012-05, Vol.97 (5), p.1615-1622

2012

Volltextzugriff (PDF)

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study

International journal of clinical practice (Esher), 2009-01, Vol.63 (1), p.46-55

2009

Volltextzugriff (PDF)

Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects

Clinical therapeutics, 2008-03, Vol.30 (3), p.513-527

2008

Volltextzugriff (PDF)

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy

Diabetes, obesity & metabolism, 2009-02, Vol.11 (2), p.167-176

2009

Volltextzugriff (PDF)

Effect of Low- and High-Fat Meals on Tacrolimus Absorption following 5 mg Single Oral Doses to Healthy Human Subjects

Journal of clinical pharmacology, 2001-02, Vol.41 (2), p.176-182

2001

Volltextzugriff (PDF)

Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects

International journal of clinical pharmacology and therapeutics, 2010-01, Vol.48 (1), p.46-58

2010

Volltextzugriff (PDF)

Pharmacokinetics of tacrolimus in liver transplant patients

Clinical pharmacology and therapeutics, 1995-03, Vol.57 (3), p.281-290

1995

Volltextzugriff (PDF)

Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: A randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes

Clinical therapeutics, 2008-03, Vol.30 (3), p.499-512

2008

Volltextzugriff (PDF)

Dose linearity after oral administration of tacrolimus 1-mg capsules at doses of 3, 7, and 10 mg

Clinical therapeutics, 1999-12, Vol.21 (12), p.2058-2064

1999

Volltextzugriff (PDF)

Demographic Considerations in Tacrolimus Pharmacokinetics

Transplantation proceedings, 1998-06, Vol.30 (4), p.1359-1364

1998

Volltextzugriff (PDF)

Combination alogliptin plus pioglitazone treatment in patients with type 2 diabetes receiving metformin

Canadian journal of diabetes, 2009, Vol.33 (3), p.257-258

2009

Volltextzugriff (PDF)

Combination alogliptin plus pioglitazone treatment in patients with type 2 diabetes inadequately controlled with diet exercise

Canadian journal of diabetes, 2009, Vol.33 (3), p.212-212

2009

Volltextzugriff (PDF)

Comparative Tacrolimus Pharmacokinetics: Normal versus Mildly Hepatically Impaired Subjects

Journal of clinical pharmacology, 2001-06, Vol.41 (6), p.628-635

2001

Volltextzugriff (PDF)

Bioequivalence of 1 and 5 mg Tacrolimus Capsules Using a Replicate Study Design

Journal of clinical pharmacology, 1999-10, Vol.39 (10), p.1032-1037

1999

Volltextzugriff (PDF)

Effect of Time of Meal Consumption on Bioavailability of a Single Oral 5 mg Tacrolimus Dose

Journal of clinical pharmacology, 2001-03, Vol.41 (3), p.289-297

2001

Volltextzugriff (PDF)

Tacrolimus oral bioavailability doubles with coadministration of ketoconazole

Clinical pharmacology and therapeutics, 1997-07, Vol.62 (1), p.41-49

1997

Volltextzugriff (PDF)

Stimulation of dopamine receptors (type 2) lowers human intraocular pressure

British journal of ophthalmology, 1985-12, Vol.69 (12), p.909-910

1985

Volltextzugriff (PDF)

Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA 1c without causing weight gain or increased hypoglycaemia

Diabetes, obesity & metabolism, 2009-12, Vol.11 (12), p.1145-1152

2009

Volltextzugriff (PDF)

Bioequivalence of a New Strength Tacrolimus Capsule Under Development

Transplantation proceedings, 1998-06, Vol.30 (4), p.1457-1459

1998

Volltextzugriff (PDF)

Dopamine-2 receptor blockade does not affect the ocular hypotensive action of timolol

British journal of ophthalmology, 1988-08, Vol.72 (8), p.598-600

1988

Volltextzugriff (PDF)

Bromocriptine lowers intraocular pressure without affecting blood pressure

The Lancet (British edition), 1983-06, Vol.1 (8336), p.1250-1251

1983

Volltextzugriff (PDF)

Coadministration of Tacrolimus and Mycophenolate Mofetil in Stable Kidney Transplant Patients: Pharmacokinetics and Tolerability

Journal of clinical pharmacology, 2000-05, Vol.40 (5), p.527-532

2000

Volltextzugriff (PDF)

Bromocriptine eyedrops lower intraocular pressure without affecting prolactin levels

The Lancet (British edition), 1984-02, Vol.1 (8371), p.287-288

1984

Volltextzugriff (PDF)

1 – 25 von 45

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(37)

Publikationsform

Artikel
(42)
Tagungsberichte
(3)

Sprache

Englisch
(45)
Japanisch
(10)

Erscheinungsjahr

n.n

Thema

Science & Technology
(34)
Humans
(32)
Life Sciences & Biomedicine
(32)
Male
(28)
Adult
(22)
Biological And Medical Sciences
(22)
Medical Sciences
(22)
Female
(20)
Pharmacology & Pharmacy
(18)
Pharmacology. Drug Treatments
(18)
Middle Aged
(14)
Double-Blind Method
(12)
Tacrolimus - Pharmacokinetics
(10)
Tacrolimus - Adverse Effects
(9)
Administration, Oral
(8)
Cross-Over Studies
(8)
Immunomodulators
(8)
Immunosuppressive Agents - Adverse Effects
(8)
Immunosuppressive Agents - Pharmacokinetics
(8)
Intraocular Pressure - Drug Effects
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA₁c without causing weight gain or increased hypoglycaemia

Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia

Efficacy and Tolerability of the DPP-4 Inhibitor Alogliptin Combined with Pioglitazone, in Metformin-Treated Patients with Type 2 Diabetes

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study

Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy

Effect of Low- and High-Fat Meals on Tacrolimus Absorption following 5 mg Single Oral Doses to Healthy Human Subjects

Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects

Pharmacokinetics of tacrolimus in liver transplant patients

Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: A randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes

Dose linearity after oral administration of tacrolimus 1-mg capsules at doses of 3, 7, and 10 mg

Demographic Considerations in Tacrolimus Pharmacokinetics

Combination alogliptin plus pioglitazone treatment in patients with type 2 diabetes receiving metformin

Combination alogliptin plus pioglitazone treatment in patients with type 2 diabetes inadequately controlled with diet exercise

Comparative Tacrolimus Pharmacokinetics: Normal versus Mildly Hepatically Impaired Subjects

Bioequivalence of 1 and 5 mg Tacrolimus Capsules Using a Replicate Study Design

Effect of Time of Meal Consumption on Bioavailability of a Single Oral 5 mg Tacrolimus Dose

Tacrolimus oral bioavailability doubles with coadministration of ketoconazole

Stimulation of dopamine receptors (type 2) lowers human intraocular pressure

Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA 1c without causing weight gain or increased hypoglycaemia

Bioequivalence of a New Strength Tacrolimus Capsule Under Development

Dopamine-2 receptor blockade does not affect the ocular hypotensive action of timolol

Bromocriptine lowers intraocular pressure without affecting blood pressure

Coadministration of Tacrolimus and Mycophenolate Mofetil in Stable Kidney Transplant Patients: Pharmacokinetics and Tolerability

Bromocriptine eyedrops lower intraocular pressure without affecting prolactin levels

Suchergebnisse filtern